Rutherford Health was the first to introduce high energy proton beam therapy to the UK and is the only centralised network in the world equipped to provide seamless patient transfer across its proton therapy centres. With every step we strive to enhance patience experience and have diagnosed or treated well over 6,000 cancer patients from across the UK and internationally.
Our state-of-the-art technology, learning opportunities and impressive clinics have attracted renowned oncologists to join us from across the UK. Through our relationship with the University of Pennsylvania, one of the world’s leading providers of PBT, we have trained more than 60 oncologists in the delivery of the treatment. The Rutherford is open to collaboration opportunities internationally with clinics and clinicians, to offer its services from the UK for international patients.
Bespoke risk assessments
The Rutherford has developed bespoke risk assessments and procedures for international patients arriving during the pandemic. Our staff has worked hard to guarantee patients a safe environment while remaining open throughout the pandemic. Our concierge services have been appreciated as reassuring and comfortable while complying to government quarantine rules. Of course, the pandemic has not slowed the onslaught of the threat of cancer for people around the world and the commitment to providing high quality, innovative care must be steadfast.
Our commitment to offering the best possible patient experience has led us to form Rutherford Panel Reviews through which oncologists and clinical teams assess the optimum treatment plan for each patient. PBT has proved to be an excellent treatment for hard-to-treat tumours as it reduces damage to surrounding healthy tissue.
Proton beam therapy
As the leading provider of proton beam therapy in the UK and one of the largest in Europe, Rutherford Health has launched the ‘Rutherford Proton Decision System’ which facilitates best practice among oncologists by making dual planning easy, efficient and inexpensive. Oncologists are able to secure a rapid comparison of treatment benefit from protons versus other radiotherapy modalities at the click of a button. The fully automated modelling system can take diagnostic images and weigh up the dosing advantage to organs at risk within a few hours without the need for a planning CT.
Partnerships and training
At Rutherford we were extremely proud to recently announce a new partnership with OncoDNA, a genomic and theranostic company specialising in precision medicine. The partnership will provide Rutherford cancer patients with access to the latest biomarker testing developed by OncoDNA and support the accessibility and development of these tests within the UK. This will help oncologists and patients identify the most effective therapy for them, as well as monitor disease progression and therapeutic response.
As well as providing wider access to proton therapy for patients from across the world, we are also looking to the future and helping train the next generation of
clinicians in the provision of PBT through our strong commitment to research, education and training.
We are partnering with a number of external professional bodies, R&D committees, universities, local clinics and NHS departments to develop our research portfolio and develop proton teaching modules, clinical training, learning and research opportunities. Our vision is to continuously enhance the rate of translation of research
and innovation into healthcare in order to create a self-improving and high-quality
health system, which is also sustainable.
Demand for proton beam therapy across the world is increasing continually. Rutherford is proud to have created a class-leading network of centres in the UK and look forward to many years more of offering effective treatment to those who need it most.
• For more information, visit: www.therutherford.com/international
